Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

PURPOSE: Single-cycle melphalan 200 mg/m(2) and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a pros...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Stadtmauer, Edward A., Pasquini, Marcelo C., Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M., Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H., Shah, Nina, Vesole, David H., Vij, Ravi, Vogl, Dan T., Giralt, Sergio, Somlo, George, Krishnan, Amrita
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553842/
https://ncbi.nlm.nih.gov/pubmed/30653422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00685
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares